Bruker has a 9/9 Piotroski score and a record of beating earnings (3 of 4 quarters, average surprise 22.8%), but weak growth, 16% short interest and a price already above the analyst target leave limited upside going into earnings in 3 days.
Thesis pillars
- Strong Piotroski Weak Margins→Stable
- Earnings Beat Record↑Improving
- Weak Growth Limits Rerating→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 27, 2026
Bruker Corporation (BRKR) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $63.79, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR, preclinical imaging), BSI CALID (mass spectrometry, diagnostics), BSI NANO, and BEST — serving life science, pharmaceutical, and industrial markets globally. About... Read more
Hold if already holding. Not a fresh buy at $63.79, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Nov 4, 2026Recent Developments — Bruker Corporation
Latest news
- NEWS Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday — benzinga Nov 4, 2026 positive
- NEWS Bruker Q3 2026 Earnings Call Transcript — benzinga Nov 4, 2026 neutral
- NEWS Bruker Reports Third Quarter 2026 Financial Results — fiscal.ai Nov 4, 2026
- NEWS Bruker Q3 Free Cash Flow $96.7M vs $(54.1)M YoY — benzinga Nov 4, 2026 positive
- NEWS Bruker Q3 GAAP Results Include $174.5M Goodwill Impairment Charge — benzinga Nov 4, 2026 negative
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicChina10-K Item 1A: 'A significant portion of our revenue is derived from sales into China... Our revenue in China for the year ended December 31, 2025, was $475.8 million'
- MEDIUMCustomerU.S. academic and government-funded customers10-K Item 1A: 'A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding'
Material Events(8-K, last 90d)
- 2026-04-10Item 5.02MEDIUMFalko Busse, Ph.D., executive officer and President of Bruker BioSpin Group, agreed to transition duties on or around May 1, 2026, with employment ending Oct 31, 2026. Separation includes severance of approx. $1.02M (CHF equivalent). No successor named.SEC filing →
- 2026-04-01Item 5.02LOWThierry L. Bernard, CEO and Managing Director of QIAGEN N.V., appointed to Board of Directors effective April 1, 2026 as Class III director, filling a newly created vacancy as Board expanded from 11 to 12 directors. No reason cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $63.79, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $55.53 reached (−12.9%), stop $59.32 (−7.5%), A.R:R -0.9:1. Score 5.3/10, moderate confidence.
Analyst target $55.53 reached (−12.9% from $63.79); no take-profit level is published. Analyst target $55.53 reached (−12.9%), stop $59.32 (−7.5%), A.R:R -0.9:1. Stop-loss: $59.32.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Weak growth.
Bruker Corporation trades at a P/E of N/A (forward 26.5). TrendMatrix value score: 5.3/10. Verdict: Hold.
20 analysts rate BRKR, with a consensus score of 3.8/5. 12 analysts publish price targets averaging $64.
What does Bruker Corporation do?Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR,...
Bruker designs and manufactures high-performance scientific instruments across four segments — BSI BioSpin (NMR, preclinical imaging), BSI CALID (mass spectrometry, diagnostics), BSI NANO, and BEST — serving life science, pharmaceutical, and industrial markets globally. About 74% of fiscal 2025 revenue came from non-U.S. operations, with major customers including pharma companies, academic institutions, and hospitals. Corporate headquarters is in Billerica, Massachusetts, with manufacturing in Europe and North America.